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Abstract: Safe and effective vaccines against hepatitis A have now been available on the market 
for almost 15 years. This review focuses on the evidence of the effect of such vaccination in 
children when applied both within routine immunization programs and in groups at high risk 
of infection, but also as a measure to stop limited or community-wide outbreaks.
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Epidemiological background
Hepatitis A virus (HAV) is present worldwide and is the agent of one of the most 
widespread infections transmitted via the fecal-oral route. In countries with poor 
hygiene and consequent wide presence of feces in the environment, the vast majority 
of subjects is infected within 5 years of age (usually without any sign or symptom of 
acute hepatitis), thus acquiring life-long immunity. Outbreaks and epidemics are rare 
due to the high herd immunity level in the population.
When socio-economic and hygienic conditions improve, the decrease of HAV 
circulation progressively leads to a decline of herd immunity. Infections usually no 
longer occur in infancy and early childhood, and susceptibility progressively expands 
to cohorts of older children, adolescent and adults, when the probability of acute dis-
ease (sometimes severe or even fulminant) increases. In these intermediate endemicity 
countries, HAV infection is transmitted both by direct contact with infected subjects 
and by ingestion of contaminated food and drinks (WHO 1995). Since HAV circula-
tion is diminished but not eliminated, both large epidemics (like the one registered 
in 1996–97 in Puglia, Italy) (Malfait et al 1996; Lopalco et al 2005) or more limited 
outbreaks (frequently starting in schools or day-care centers) can occur.
The incidence of HAV shows a cyclic pattern, with years of peaks and years of 
troughs. In the USA, for instance, peaks of incidence occurred in 1954, 1961, 1971, 
and 1989 (Wasley et al 2005).
In countries with very low HAV endemicity, high hygienic standards substantially 
limit viral spread. Outbreaks are rare, and hepatitis A is typically considered to be a 
travellers’ infection (although this notion has partially been modiﬁ  ed in recent times by 
increasing migration patterns and increasing importation of exotic foods: “hepatitis A 
is also travelling to us”). In low endemicity countries, subjects infected during travels 
abroad represent a potential source of infection for others once returned at home.
Immuonogenicity and efﬁ  cacy of hepatitis A 
vaccines
Several inactivated vaccines and one live attenuated vaccine (Mao et al 1997) (widely 
used in China) are currently available. The development of inactivated hepatitis A 
vaccines dates back to the end of the 1980s. Both preregistration clinical trials and Therapeutics and Clinical Risk Management 2007:3(6) 1072
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large-scale experiences of use showed that such vaccines 
are strongly and rapidly immunogenic. The minimal level 
of anti-HAV able to confer protection after vaccination has 
not been deﬁ  nitely established. Seroconversion is usually 
deﬁ  ned as the attainment of an antibody titer between 10 
and 20 mIU/mL of anti-HAV . Such concentration, normally 
detected in those who received standard immune globulins 
two months before, was shown to be able to prevent HAV 
infection (Bell et al 2004). However, it must be stressed that 
cellular immunity plays a fundamental role for protection, and 
that production of anti-HAV following active immunization 
is certainly directly related to the availability of neutralizing 
antibodies but, even more importantly, is an indirect means 
of showing that immune memory has been established.
The majority of subjects are already seroconverts two weeks 
after a single dose. The percentage reaches 95%–100% 4 weeks 
after the ﬁ  rst vaccine administration (Werzberger et al 1992; 
Crovari et al 1992; Nalin et al 1993; Van Damme et al 1994).
With regard to immunogenicity of hepatitis A vaccines in 
children and adolescents, it must be noted that although since 
the mid-1990s the vaccination schedule speciﬁ  es administra-
tion of two doses only (6 to 18 months apart), data on the ﬁ  rst 
vaccination experiences relate to the formerly used 3-dose 
schedule (0, 1, 6 month). Two such studies of long-term 
follow-up consistently showed 100% seroconversion at month 
7 (ie, one month after the last dose), when antibody titer also 
peaked (Geometric Mean Titers or GMTs of anti-HAV of 
4133 and 3802 mIU/mL, respectively) (Fan et al 1998; Chan 
et al 1999). All children in the two studies were still anti-HAV 
positive at month 60 of follow-up. A study of ﬁ  eld efﬁ  cacy 
with a different vaccine also showed antibody persistence up 
to 9 years after immunization (Wiens et al 1996; Werzbereger 
et al 1998, 2002). Mathematical models of antibody kinetics 
reported in the same papers predict a persistence of anti-HAV 
at detectable level for 14–30 years, but immune memory is 
expected to last much longer, making the need for booster 
doses later in life unlikely (Van Damme et al 2003).
An interesting study based on the two-dose administration 
schedule was performed on children in Alaska. The second 
dose was administered in delay, with a mean interval of 
27 months, but seroconversion to anti-HAV occurred all the 
same, although 17% of subjects were seronegative before 
the booster dose (Williams et al 2000). This result is further 
proof that immune memory is already obtained in virtually 
all subjects after a single dose of vaccine.
An experimental demonstration of the role of immuno-
logical memory was provided by studies on chimpanzees, 
which resulted in protection against a challenge with HAV 
even in the absence of detectable anti-HAV (Purcell et al 
1992).
A speciﬁ  c issue of hepatitis A vaccination at pediatric 
age is represented by active immunization in the ﬁ  rst two 
years of life, since maternal antibodies might theoretically 
interfere with response to vaccination.
Although lower seroconversion rates and GMTs of 
anti-HAV were detected in infants born to seropositive in 
comparison to those born to seronegative mothers just after 
the completion of the vaccination course, priming of immune 
memory occurs (as demonstrated by the similar anamnestic 
response to a booster dose detected in subjects from both 
groups) independently from the serological status of the mother 
(Piazza et al 1999; Dagan et al 2000; Fiore et al 2001).
With regard to efﬁ  cacy of vaccination, two studies 
performed using inactivated vaccines (Vaqta and Havrix, 
respectively), demonstrated the excellent protection 
afforded by active immunization. In the ﬁ  rst study, over 
1000 subjects (age range 2–16 years) in a New York City 
community with high hepatitis A incidence were randomly 
assigned to vaccine or to placebo. Except for a vaccinated 
subject who was already incubating the disease (onset of 
acute hepatitis A 3 weeks after immunization), no other 
immunized child became ill, compared with 34 cases of 
hepatitis A that occurred in the placebo recipient group. 
The protective efﬁ  cacy was therefore 100% (lower limit 
of 95% conﬁ  dence interval [CI]: 87%) (Werzberger et al 
1993). The other study involved over 40,000 Thai children 
living in villages with a high incidence of hepatitis A and 
aimed at evaluating the effectiveness of two doses of vac-
cine given one month apart. Effectiveness was 94% (95% 
CI: 79%–99%) (Innis et al 1994). The observation that in 
these trials no case of hepatitis A occurred starting from 
17 days following the ﬁ  rst vaccine administration suggests 
also the potential for a post-exposure protective efﬁ  cacy of 
inactivated hepatitis A vaccines (see following chapter on 
outbreak control).
Safety of hepatitis A vaccines
Adverse reactions to hepatitis A vaccination are infrequent 
and generally mild. The most common side-effects are rep-
resented by pain, swelling and redness at the injection site, 
usually of low-grade, and spontaneously resolving in a few 
hours or days. Such events were reported by less than 25% 
of vaccinated subjects during a pre-registration clinical trial 
of an inactivated hepatitis A vaccine (Crovari et al 1992). In 
other studies, pain at the injection site was reported by up to 
56% of vaccinees (CDC 1999). Other adverse events related Therapeutics and Clinical Risk Management 2007:3(6) 1073
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to vaccine administration include headache, fatigue, fever, 
diarrhea, and vomiting. If we exclude headache (reported by 
about 15% of subjects), the percentage of such systemic reac-
tions is below 5%. Temporal associations between hepatitis A 
vaccine administration and serious reactions such as anaphy-
laxis, Guillain-Barré syndrome, brachial plexus neuropathy, 
transverse myelitis, multiple sclerosis, encephalopathy, and 
erythema multiforme were reported (Bell et al 2004). How-
ever, after 65 million doses were administered worldwide 
and following a revision of data from different sources col-
lected over 5 years, no serious adverse event was deemed to be 
causally related to hepatitis A vaccine. Data of the US system 
of collection of adverse reactions following immunization 
(Vaccine Adverse Events Reporting System [VAERS]) show 
that, for those adverse reactions whose background incidence 
is known, rates reported in vaccinees are not higher than those 
found in unvaccinated subjects (CDC 1999).
Impact of hepatitis A vaccination: 
outbreak control and routine 
immunization
Industrialized countries usually belong to low or very low 
endemicity regions, but several examples exist of particular 
areas within these nations characterized by an intermediate 
endemicity pattern. For example, Puglia in Italy, Catalonia 
in Spain, the North Bohemian region in the Czech Republic, 
the south-western states and Alaska in the USA, the whole 
state of Israel, can be considered as areas where the periodi-
cal occurrence of large outbreaks or even epidemics make 
hepatitis A an important public health issue.
The World Health Organization recommends that 
hepatitis A vaccination be considered for introduction into 
routine childhood immunization schedules in countries at inter-
mediate endemicity of infection where hepatitis A represents a 
signiﬁ  cant public health problem. Economic and epidemiologi-
cal studies should precede decisions on universal vaccination 
policies (WHO 2000). In other low endemicity countries, hepa-
titis A vaccine should be administered to subjects belonging to 
high risk groups like international travelers, military personnel 
involved in missions abroad, children of immigrant families, 
intravenous drug users, patients with clotting factor disorders, 
patients affected with chronic hepatitis, homosexual men, and 
so on. Some countries also have recommendations for use of 
hepatitis A vaccination during outbreaks.
Policies of immunization targeted at risk groups, while 
effective for individual protection, usually fail to control the 
spread of an infectious agent on a community basis due to 
the difﬁ  culty in identifying those at risk and in effectively 
implementing their vaccination (as already demonstrated in 
the past by the experience with hepatitis B vaccine) (Bonanni 
1995). Nevertheless, where routine vaccination programs 
against hepatitis A are not applied due to generally low ende-
micity but with periodic outbreaks, immunization of those 
in close contact with cases has proved useful in shortening 
outbreak duration, provided that a sufﬁ  cient proportion of 
subjects is reached by immunization.
In areas at high endemicity for HAV infection, some 
experiences of control of epidemics using standard immune 
globulins had demonstrated the inability of such preventive 
means to get a long-lasting effect (Shaw et al 1986).
The ﬁ  rst attempt to stop an outbreak by using a vaccine 
dates back to 1992, in Alaska, when immunization with a 
single dose was widely offered to all subjects under 40 years 
of age, to nonimmune older individuals in the Tok/Glenallen 
area, to all subjects under 20, and to seronegative subjects in 
the age range 20–34 in the Kotzebue area. It was possible to 
demonstrate that the attack rate of HAV infection in the ﬁ  rst 
60 weeks following vaccination was 12% in unimmunized 
subjects and 2.1% in vaccinees (most cases occurring few 
days after active immunization, ie, they were vaccinated 
during the incubation period). In the Kotzebue area, where 
only about 50% of eligible individuals were immunized, the 
epidemic persisted for several weeks, while in the surround-
ing regions, where coverage reached 80%, the epidemic 
was virtually eliminated within 8 weeks from the start of 
vaccination program (Mc Mahon et al 1996).
Other experiences in communities of American Indians 
showed that routine vaccination of children can interrupt 
already occurring epidemics, and that keeping up coverage 
prevents the start of new epidemics (CDC 1999).
In Europe, an intervention conducted in two villages 
in Slovakia where an epidemic was occurring (121 cases 
between December 1991 and March 1993, 62 of which in 
schoolchildren), caused its extinction two months after 2/3 
of children were immunized with two doses of vaccine, 
with only nine further cases before the end of the epidemic 
in March 1993, 8 of which were in the nonvaccinated group 
(Prikazsky et al 1994).
Several outbreaks have occurred in Europe originating in 
day-care centers, and maternal or primary schools (sometimes 
with spread to the larger community) where vaccination was 
used in the attempt to shorten the duration of such episodes.
Almost all outbreaks of this kind originate from 
children of immigrant families born in their adoptive 
country who periodically travel back (usually in summer) Therapeutics and Clinical Risk Management 2007:3(6) 1074
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to their country of origin to visit relatives. The infected 
children are contagious when school activities start again, 
and characteristic patterns of HAV transmission to indig-
enous European children and to the parents (typically 
about 1 month after the wave in children) are observed 
(van Gorkom et al 1998).
The 11 cases (5 in children and 6 in household contacts) 
detected in a nursery school in Central Italy resulted in one of 
the ﬁ  rst attempts to stop imported outbreaks in schools by using 
hepatitis A vaccination. The program of immunization was 
accepted by almost all other schoolchildren and school per-
sonnel, and by 11/36 cohabitant children and 10/78 cohabitant 
adults of cases. The last case was detected two months after the 
start of vaccination, a considerably shorter interval compared 
to previous similar outbreaks (Bonanni et al 1998).
More recently, two outbreaks (again originating from 
immigrant children) occurred almost simultaneously on 
two sides of the city of Florence, Italy, but had very differ-
ent outcomes. During the ﬁ  rst outbreak on the southeastern 
side of the city, the index case was identiﬁ  ed with consider-
able delay, and the immunization program of case contacts 
started late as a result of poor communication within the local 
health unit and the unavailability of a sufﬁ  cient number of 
doses. Compliance with the Italian guidelines on hepatitis 
A vaccine use, which suggest waiting for a second case to 
occur in secondary schools before starting vaccination of 
contacts, meant that the infection spread to adolescents and 
their relatives. Overall, 30 clinically overt cases and 7 asymp-
tomatic infections were detected, and the outbreak lasted 
for 6 months. On the other hand, a potential outbreak in a 
maternal school was stopped in the northwestern part of the 
city because a vaccination program of other schoolchildren 
and of contacts of the index case was immediately imple-
mented, reaching 80% coverage. Only 3 cases of hepatitis 
A occurred, one of which may have been connected to other 
sources of infection. Comparing the two outbreaks enables 
us to draw some conclusions on the use of hepatitis A vac-
cine to stop the virus spreading in schools and households. 
Most important is timely diagnosis of hepatitis A by general 
practitioners, improved communication channels within the 
health care setting, the availability of a sufﬁ  cient number of 
vaccine doses in every health district for immediate use in 
case of an outbreak, and the offer of immunization to case 
contacts irrespective of a presumed ‘low-risk’ environment, 
such as secondary schools (Bonanni et al 2005).
To establish individual protection by hepatitis A vaccine 
in post-exposure prophylaxis, Hepatitis A vaccine was used 
in HAV susceptible family contacts of acute hepatitis A cases 
(173 vaccinated and 178 unvaccinated) in a randomized, 
controlled trial.
Hepatitis A vaccine showed an 82% protective efﬁ  cacy 
(95% CI: 20%–96%) in the prevention of secondary cases 
(79%; 95% CI: 7%–95%, when households were analysed). 
About 56% of subjects had been immunised within 4 days 
from the onset of symptoms in primary cases, and 100% 
within 8 days. Vaccination was required in 18 participants to 
prevent one secondary infection (Sagliocca et al 1999).
Evidence that clinical disease does not occur at antibody 
levels lower than those currently accepted as protective, that 
hepatitis A vaccine has proved effective in controlling out-
breaks, and that timely immunization can prevent secondary 
infections within households, strongly suggests the useful-
ness of immunization against hepatitis A in traveler children, 
even for last-minute departures (Connor 2005).
In the last 10 years, the health authorities of some of the coun-
tries mentioned above, characterized by generally low endemicity 
but with areas at intermediate endemicity, introduced universal 
immunization policies with different target populations. We can 
now evaluate the epidemiological effects of such decisions.
In the United States in 1999, the Advisory Committee on 
Immunization Practices (ACIP) issued new recommendations 
on the public health use of hepatitis A vaccine, amending those 
of 1996 which focused on vaccinating subjects at risk. The 
ACIP stated that “… a review of the national epidemiologic 
data indicates that continued implementation of these recom-
mendations would not result in vaccination of most popula-
tions with consistently elevated rates of disease and therefore 
would have a limited impact on the overall incidence of dis-
ease in the United States. To achieve a sustained reduction in 
HAV rates, a shift is needed to one that achieves widespread 
routine vaccination of children to prevent infection in these 
age groups and eventually among older persons.”
As a consequence, routine vaccination of children was 
recommended in states, counties and communities with rates 
of infection more than double the national average (20 
cases per 100,000 population) and should also be considered 
if infection rates were 10 cases but 20 cases per 100,000 
population (CDC 1999). These recommendations recognized 
both the role that children play in transmitting HAV to others 
and the value of population-level action (Poland 2005).
A recently published study aimed at assessing the impact 
of the current vaccination strategy by evaluating trends in 
reported cases of hepatitis A since implementation of the recom-
mendations (Wasley et al 2005). Incidence rates in 2003 were 
compared with those for the prevaccination baseline period 
(1990–1997) overall and in the 17 states in which children Therapeutics and Clinical Risk Management 2007:3(6) 1075
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should routinely be vaccinated, or considered for routine 
vaccination (vaccinating states). Incidence rates in vaccinating 
states were also compared with those in the remaining states 
where there is no recommendation for statewide vaccination of 
children (non-vaccinating states). Between the baseline period 
(1990–1997) and 2003, overall hepatitis A rates declined 76% to 
2.6 per 100,000, signiﬁ  cantly lower than previous lowest points 
in 1983 (9.2/100,000) and 1992 (9.1/100,000). The rate in vac-
cinating states declined 88% to 2.5 per 100,000 compared with 
53% elsewhere (to 2.7/100,000). Declines were greater among 
children aged 2 to 18 years (87%) than among persons older than 
age 18 years (69%); the proportion of cases in children dropped 
from 35% to 19%. Since 2001, rates in adults have been higher 
than among children, with the highest rates now among men 
aged 25 through 39 years.
After implementation of routine hepatitis A vaccination 
of children, hepatitis A rates have declined to historic lows, 
accompanied by substantial changes in the epidemiologic 
proﬁ  le. Although the precise contribution of vaccination is 
difﬁ  cult to assess, given the unavailability of detailed data on 
vaccination coverage in different states and areas, neverthe-
less the declines of incidence registered after 1999 have been 
unprecedented in magnitude and greater in areas in which 
vaccination of children is occurring.
As a consequence of the documented impact of hepa-
titis A vaccination on HAV epidemiology, the US health 
authorities very recently extended the recommendations for 
hepatitis A routine immunization. Hepatitis A vaccination is 
now recommended for all children at age 1 year (ie, 12–23 
months). The 2 doses in the series should be administered at 
least 6 months apart. States, counties, and communities with 
existing hepatitis A vaccination programs for children aged 
2–18 years are encouraged to maintain these programs. In these 
areas, new efforts focused on routine vaccination of children 
aged 1 year should enhance, not replace, ongoing programs 
directed at a broader population of children (CDC 2006).
Another proof of the impact of routine vaccination 
programs against hepatitis A on the epidemiology of this 
infection comes from the Israeli experience. In Israel, the 
mean annual incidence of hepatitis A disease was 50.4 per 
100,000 during 1993–98. A 2-dose universal hepatitis A 
immunization program aimed at children aged 18–24 months 
(without a catch-up campaign) was started in 1999. Incidence 
of reported hepatitis A disease was monitored in the years 
1993–2004. Overall vaccine coverage in Israel in 2001–02 
was 90% for the ﬁ  rst dose and 85% for the second dose. A 
decline in disease rates was observed before 1999 among the 
Jewish but not the non-Jewish population. After initiation of 
the program, a sharp decrease in disease rates was observed 
in both populations. The annual incidence of 2.2 to 2.5 per 
100,000 during 2002–04 represents a 95% or greater reduc-
tion for each year with respect to the mean incidence during 
1993–98 (p  0.001).
For children aged 1 through 4 years, a 98.2% reduction 
in disease was observed in 2002–04, compared with the pre-
vaccination period (p  0.001). However, a sharp decline 
was also observed in all other age groups. In the Jewish 
population in the Jerusalem district, among whom an active 
surveillance program was successfully conducted, a more 
than 90% reduction of disease was demonstrated. Of the 433 
cases reported nationwide in 2002–04 in whom vaccination 
status could be ascertained, 424 (97.9%) received no vac-
cine and none received 2 doses. This universal toddlers-only 
immunization program in Israel demonstrated not only high 
effectiveness of hepatitis A vaccination but also marked 
herd protection, challenging the need for catch-up hepatitis 
A vaccination programs (Dagan et al 2005).
Similar results were obtained in Puglia, Italy and in Catatonia, 
Spain, where routine vaccination of children in the second year 
of life (Puglia) and/or at adolescent age (Puglia and Catatonia) 
concomitantly with hepatitis B vaccination were recommended 
at the end of the 1990s (Lopalco et al 2000). Epidemiologic 
surveillance shows that peaks of hepatitis A incidence cyclically 
occurring in the past, were no longer observed in these areas.
Conclusion
Hepatitis A vaccine is one of the most immunogenic vaccines 
available. Its excellent efﬁ  cacy in pre-exposure prophylaxis 
has been documented by several studies. Vaccination has 
been used (mainly targeting children) in the course of out-
breaks and for the prevention of secondary cases.
Active prophylaxis usually shortened the course of out-
breaks where coverage reached about 80% of a well-deﬁ  ned 
target population.
No clinical trial on the effectiveness of HA vaccination 
during outbreaks (in comparison with human normal immune 
globulin) is available. Although used in the past for post-
exposure prophylaxis, immune globulin preparations have 
decreased their antibody concentrations, are difﬁ  cult to get and 
are not well accepted due to their origin from human blood.
The only clinical trial of vaccine used for post-exposure 
prophylaxis showed good efﬁ  cacy (about 80%). However, 
conﬁ  dence intervals are wide, and large numbers of subjects 
for study are very difﬁ  cult to obtain.
In communities experiencing recurrent epidemics or 
outbreaks, the use of vaccination seems justiﬁ  ed by the high Therapeutics and Clinical Risk Management 2007:3(6) 1076
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secondary attack rates and the consequent acceptable cost-
effectiveness proﬁ  le.
However, the implementation of routine vaccination of 
children and/or adolescents, which has recently proved very 
effective in its effect on general HAV epidemiology, seems, 
in the long term, the most reasonable way to get recurrent 
outbreaks under control in areas where hepatitis A represents 
a public health problem.
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